Metoclopramide Use in Anorexia Nervosa

Primary Safety Concerns

The FDA warns against metoclopramide use beyond 12 weeks due to severe adverse effects, including extrapyramidal symptoms and tardive dyskinesia, in patients with anorexia nervosa who require prolonged treatment 1, 2
Metoclopramide can cause central nervous system effects, such as somnolence, depression, and hallucinations, particularly concerning in anorexia nervosa patients with significant psychiatric comorbidity 3
The risk of extrapyramidal symptoms, including acute dystonic reactions, drug-induced parkinsonism, and akathisia, is increased with metoclopramide use in anorexia nervosa patients 1, 2
Tardive dyskinesia, a potentially irreversible movement disorder, can persist even after metoclopramide discontinuation in anorexia nervosa patients 1, 2

Nutritional rehabilitation is the primary treatment for gastrointestinal symptoms in anorexia nervosa, and symptoms typically improve with weight restoration 4
Dietary modifications, such as small, frequent meals with liquid calories and small particle size foods, can help manage gastrointestinal symptoms in anorexia nervosa patients 1, 2
Comprehensive psychiatric treatment, including evidence-based psychotherapy, is essential for addressing the core eating disorder pathology in anorexia nervosa patients 4
If severe gastroparesis persists after weight restoration, metoclopramide should only be reserved for the most severe, refractory cases unresponsive to all other therapies, with careful monitoring and time-limited use 1, 2

The American College of Gastroenterology and other guideline societies implicitly caution against treating gastrointestinal symptoms of anorexia nervosa as primary gastroparesis requiring prokinetic agents, as this approach exposes patients to serious neurological risks without addressing the underlying eating disorder pathology 1, 2, 4